{"id":37530,"title":"Weight Loss Drugs Could Transform Treatment of Multiple Chronic Diseases Research Shows","publisher":"Stockmark.IT","author":"Stockmark.IT Website","published":"2024-12-13T07:02:05+00:00","modified":"2024-12-13T07:02:05+00:00","canonical_url":"https://stockmark.it/weight-loss-drugs-could-transform-treatment-of-multiple-chronic-diseases-research-shows/","markdown_url":"https://stockmark.it/weight-loss-drugs-could-transform-treatment-of-multiple-chronic-diseases-research-shows.md","json_url":"https://stockmark.it/weight-loss-drugs-could-transform-treatment-of-multiple-chronic-diseases-research-shows.json","category":"Healthcare","categories":["Healthcare","Medical Research","Pharmaceutical"],"featured_image":"https://i0.wp.com/stockmark.it/wp-content/uploads/stencil.stockmark-it-2024-12-13T070150.972.jpg?fit=1200%2C800&quality=89&ssl=1","format":"news","language":"en-GB","content":"Groundbreaking research indicates that popular weight-loss medications like Ozempic, Wegovy, and Mounjaro might have far-reaching applications beyond obesity treatment, potentially revolutionising the approach to various chronic conditions.\n\nDr Mo Sarhan, a Florida-based physician, has witnessed remarkable success using Eli Lilly’s Mounjaro to treat patients with opioid and alcohol addictions. His team has administered glucagon-like peptide-1 receptor agonists (GLP-1s) to approximately 75 patients, yielding what he describes as “compelling” results.\n\nEli Lilly’s chief executive, Dave Ricks, has announced the company’s plans to launch extensive studies investigating GLP-1s’ effectiveness in treating alcohol, nicotine, and drug abuse. This marks the first major pharmaceutical company to explore these applications systematically.\n\nThe market potential for these drugs is substantial, with Goldman Sachs analysts projecting a £130 billion market by 2030. Novo Nordisk is currently conducting three late-stage trials of semaglutide for Alzheimer’s disease, whilst early studies suggest promise in treating Parkinson’s disease symptoms.\n\nThe therapeutic mechanisms remain partially unclear, though research indicates the drugs may influence pleasure pathways in the brain similarly to how they suppress appetite. Beyond weight loss, GLP-1s have demonstrated impressive cardiovascular benefits, with studies showing a 28 per cent reduction in heart attack risk.\n\nDespite the promising outlook, challenges persist. The current high cost of these medications – approximately £1,349 per month in the US – poses a significant barrier to widespread adoption. Additionally, side effects including nausea and fatigue have led to a 30 per cent discontinuation rate within the first month of use.\n\nThe pharmaceutical industry’s focus remains primarily on the lucrative obesity market, potentially limiting research into other applications. However, as understanding of these drugs grows and more affordable options emerge, they could transform the treatment landscape for numerous chronic conditions."}